FRISC-II at 15 Years

The overall advantage of an early invasive strategy for non–ST-elevation ACS persisted during long-term follow-up, but not thanks to a survival benefit.

In the randomized FRISC-II trial, patients from Sweden, Denmark, and Norway with non–ST-elevation acute coronary syndrome (NSTEACS) had lower risk for death or myocardial infarction (MI) with an early invasive strategy than a noninvasive strategy, even at 5 years (NEJM JW Gen Med Nov 15 2006 and Lancet 2006; 368:998). Other analyses suggested that the invasive strategy's benefit was limited to men and to patients with elevated troponin levels. Investigators now report 15-year follow-up data on the 2457 FRISC II participants (mean age, 66; 70% men); 99% had 15-year mortality data, and fewer (89%) had 15-year data on other endpoints, mostly because of administrative difficulties in Norway.

The early invasive strategy was associated with postpo…

Reviewing Author

Harlan M. Krumholz, MD, SM

Disclosures

Consultant/Advisory BoardUnited Healthcare; Element Science; Eyedentifeye, F-Prime

EquityHugo Health; Refactor Health; Element Science

Grant/Research SupportPfizer; Agency for Healthcare Research and Quality; Janssen Research and Development, National Institute of Biomedical Imaging and Engineering; National Heart, Lung, and Blood Institute; Centers for Disease Control and Prevention; National Cancer Institute; American Heart Association

Harlan M. Krumholz, MD, SM

Disclosures

Consultant/Advisory BoardUnited Healthcare; Element Science; Eyedentifeye, F-Prime

EquityHugo Health; Refactor Health; Element Science

FRISC-II at 15 Years

Topics

Reviewing Author